{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:47:28Z","timestamp":1791305248604,"version":"4.3.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1245\/s10434-025-18887-1","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T17:56:20Z","timestamp":1766166980000},"page":"3425-3434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Paradox of Grade 2 Pancreatic Neuroendocrine Tumors: G2a\/G2b Subdivision in Patients With and Without Liver Metastases: A Retrospective Single-Center Analysis"],"prefix":"10.1245","volume":"33","author":[{"given":"Vanja","family":"Podrascanin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallbera","family":"Gudmundsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Santol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pereyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius A.","family":"Thiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne G.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Truty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Kendrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Nagorney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick P.","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"18887_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.15798","volume":"8","author":"A Dasari","year":"2025","unstructured":"Dasari A, Wallace K, Halperin DM, et al. Epidemiology of neuroendocrine neoplasms in the US. JAMA Netw Open. 2025;8:e2515798. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.15798.","journal-title":"JAMA Netw Open."},{"key":"18887_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/oncolo\/oyac049","volume":"27","author":"MB Sonbol","year":"2022","unstructured":"Sonbol MB, Mazza GL, Mi L, et al. Survival and incidence patterns of pancreatic neuroendocrine tumors over the last 2 decades: a SEER database analysis. Oncologist. 2022;27:573\u20138. https:\/\/doi.org\/10.1093\/oncolo\/oyac049.","journal-title":"Oncologist."},{"key":"18887_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:839\u201368. https:\/\/doi.org\/10.6004\/jnccn.2021.0032.","journal-title":"J Natl Compr Canc Netw."},{"key":"18887_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u20138. https:\/\/doi.org\/10.1111\/his.13975.","journal-title":"Histopathology."},{"key":"18887_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jne.70003","volume":"37","author":"H Gudmundsdottir","year":"2025","unstructured":"Gudmundsdottir H, Graham RP, Greipp PT, et al. Alternative lengthening of telomeres and Ki-67 proliferation index provide complementary information on recurrence risk after resection of pancreatic neuroendocrine tumors. J Neuroendocrinol. 2025;37:e70003. https:\/\/doi.org\/10.1111\/jne.70003.","journal-title":"J Neuroendocrinol."},{"key":"18887_CR6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1136\/gutjnl-2020-322595","volume":"71","author":"WM Hackeng","year":"2022","unstructured":"Hackeng WM, Brosens LAA, Kim JY, et al. Non-functional pancreatic neuroendocrine tumours: ATRX\/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX\/PDX1 expression and tumour size. Gut. 2022;71:961\u201373. https:\/\/doi.org\/10.1136\/gutjnl-2020-322595.","journal-title":"Gut."},{"key":"18887_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/MPA.0000000000000990","volume":"47","author":"P Philips","year":"2018","unstructured":"Philips P, Kooby DA, Maithel S, et al. Grading using Ki-67 index and mitotic rate increases the prognostic accuracy of pancreatic neuroendocrine tumors. Pancreas. 2018;47:326\u201331. https:\/\/doi.org\/10.1097\/MPA.0000000000000990.","journal-title":"Pancreas."},{"key":"18887_CR8","doi-asserted-by":"publisher","first-page":"18919","DOI":"10.1038\/s41598-025-04356-y","volume":"15","author":"Y Kageyama","year":"2025","unstructured":"Kageyama Y, Ashida R, Ohike N, et al. Stratification of G2 pancreatic neuroendocrine tumors using a ten percent Ki-67 index cut-off based on clinicopathological and molecular analyses. Sci Rep. 2025;15:18919. https:\/\/doi.org\/10.1038\/s41598-025-04356-y.","journal-title":"Sci Rep."},{"key":"18887_CR9","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1245\/s10434-024-15632-y","volume":"31","author":"OC Eren","year":"2024","unstructured":"Eren OC, Bagci P, Balci S, et al. Subgrading of G2 pancreatic neuroendocrine tumors as 2A (Ki67 3% to <10%) versus 2B (10% to \u226420%) identifies behaviorally distinct subsets in keeping with the evolving management protocols. Ann Surg Oncol. 2024;31:7001\u201311. https:\/\/doi.org\/10.1245\/s10434-024-15632-y.","journal-title":"Ann Surg Oncol."},{"key":"18887_CR10","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1097\/PAS.0000000000000089","volume":"37","author":"CM McCall","year":"2013","unstructured":"McCall CM, Shi C, Cornish TC, et al. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. Am J Surg Pathol. 2013;37:1671\u20137. https:\/\/doi.org\/10.1097\/PAS.0000000000000089.","journal-title":"Am J Surg Pathol."},{"key":"18887_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00534-005-0999-7","volume":"12","author":"SM Strasberg","year":"2005","unstructured":"Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12:351\u20135. https:\/\/doi.org\/10.1007\/s00534-005-0999-7.","journal-title":"J Hepatobiliary Pancreat Surg."},{"key":"18887_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg."},{"key":"18887_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11605-013-2423-y","volume":"18","author":"K Fukushima","year":"2014","unstructured":"Fukushima K, Fukumoto T, Kuramitsu K, et al. Assessment of ISGLS definition of posthepatectomy liver failure and its effect on outcome in patients with hepatocellular carcinoma. J Gastrointest Surg. 2014;18:729\u201336. https:\/\/doi.org\/10.1007\/s11605-013-2423-y.","journal-title":"J Gastrointest Surg."},{"key":"18887_CR14","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.surg.2016.11.014","volume":"161","author":"C Bassi","year":"2017","unstructured":"Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161:584\u201391. https:\/\/doi.org\/10.1016\/j.surg.2016.11.014.","journal-title":"Surgery."},{"key":"18887_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.surg.2007.02.001","volume":"142","author":"MN Wente","year":"2007","unstructured":"Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142:20\u20135. https:\/\/doi.org\/10.1016\/j.surg.2007.02.001.","journal-title":"Surgery."},{"key":"18887_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.surg.2007.05.005","volume":"142","author":"MN Wente","year":"2007","unstructured":"Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761\u20138. https:\/\/doi.org\/10.1016\/j.surg.2007.05.005.","journal-title":"Surgery."},{"key":"18887_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, Von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. https:\/\/doi.org\/10.1371\/journal.pmed.0040297.","journal-title":"PLoS Med."},{"key":"18887_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s12020-020-02475-2","volume":"71","author":"ME Caplin","year":"2021","unstructured":"Caplin ME, Pavel M, Phan AT, et al. Lanreotide autogel\/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021;71:502\u201313. https:\/\/doi.org\/10.1007\/s12020-020-02475-2.","journal-title":"Endocrine."},{"key":"18887_CR19","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, et al. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403:2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet."},{"key":"18887_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000225952","volume":"90","author":"R Arnold","year":"2009","unstructured":"Arnold R, Chen YJ, Costa F, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: follow-up and documentation. Neuroendocrinology. 2009;90:227\u201333. https:\/\/doi.org\/10.1159\/000225952.","journal-title":"Neuroendocrinology."},{"key":"18887_CR21","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/JCO.23.01529","volume":"41","author":"J Del Rivero","year":"2023","unstructured":"Del Rivero J, Perez K, Kennedy EB, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41:5049\u201367. https:\/\/doi.org\/10.1200\/JCO.23.01529.","journal-title":"J Clin Oncol."},{"key":"18887_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/jso.25811","volume":"121","author":"Y Kasai","year":"2020","unstructured":"Kasai Y, Hirose K, Corvera CU, et al. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis. J Surg Oncol. 2020;121:330\u20136. https:\/\/doi.org\/10.1002\/jso.25811.","journal-title":"J Surg Oncol."},{"key":"18887_CR23","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","volume":"24","author":"M Fairweather","year":"2017","unstructured":"Fairweather M, Swanson R, Wang J, et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24:2319\u201325. https:\/\/doi.org\/10.1245\/s10434-017-5839-x.","journal-title":"Ann Surg Oncol."},{"key":"18887_CR24","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1245\/s10434-023-13372-z","volume":"30","author":"H Gudmundsdottir","year":"2023","unstructured":"Gudmundsdottir H, Habermann EB, Vierkant RA, et al. Survival and symptomatic relief after cytoreductive hepatectomy for neuroendocrine tumor liver metastases: long-term follow-up evaluation of more than 500 patients. Ann Surg Oncol. 2023;30:4840\u201351. https:\/\/doi.org\/10.1245\/s10434-023-13372-z.","journal-title":"Ann Surg Oncol."},{"key":"18887_CR25","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1007\/s12029-024-01077-9","volume":"55","author":"SA Pandrowala","year":"2024","unstructured":"Pandrowala SA, Kapoor D, Kunte A, et al. Factors predicting prognosis in metastatic grade 1 gastro-entero-pancreatic neuroendocrine tumors. J Gastrointest Cancer. 2024;55:1220\u20138. https:\/\/doi.org\/10.1007\/s12029-024-01077-9.","journal-title":"J Gastrointest Cancer."},{"key":"18887_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/00000658-200210000-00001","volume":"236","author":"WR Jarnagin","year":"2002","unstructured":"Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg. 2002;236:397\u2013407. https:\/\/doi.org\/10.1097\/00000658-200210000-00001.","journal-title":"Ann Surg."},{"key":"18887_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/cancers16010100","volume":"16","author":"S M\u00f8ller","year":"2023","unstructured":"M\u00f8ller S, Langer SW, Slott C, et al. Recurrence-free survival and disease-specific survival in patients with pancreatic neuroendocrine neoplasms: a single-center retrospective study of 413 patients. Cancers. 2023;16:100. https:\/\/doi.org\/10.3390\/cancers16010100.","journal-title":"Cancers."},{"key":"18887_CR28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.surg.2018.04.070","volume":"165","author":"AT Scott","year":"2019","unstructured":"Scott AT, Breheny PJ, Keck KJ, et al. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165:166\u201375. https:\/\/doi.org\/10.1016\/j.surg.2018.04.070.","journal-title":"Surgery."},{"key":"18887_CR29","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0321","volume":"32","author":"P Bourdeleau","year":"2025","unstructured":"Bourdeleau P, Pokossy-Ep\u00e9e J, Hentic O, et al. Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2025;32:e240321. https:\/\/doi.org\/10.1530\/ERC-24-0321.","journal-title":"Endocr Relat Cancer."},{"key":"18887_CR30","doi-asserted-by":"publisher","first-page":"941210","DOI":"10.3389\/fendo.2022.941210","volume":"13","author":"WH Zhang","year":"2022","unstructured":"Zhang WH, Gao HL, Liu WS, et al. A real-life treatment cohort of pancreatic neuroendocrine tumors: high-grade increase in metastases confers poor survival. Front Endocrinol. 2022;13:941210. https:\/\/doi.org\/10.3389\/fendo.2022.941210.","journal-title":"Front Endocrinol."},{"key":"18887_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/pas.0b013e31821a0696","volume":"35","author":"Z Yang","year":"2011","unstructured":"Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67-labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35:853\u201360. https:\/\/doi.org\/10.1097\/pas.0b013e31821a0696.","journal-title":"Am J Surg Pathol."},{"key":"18887_CR32","doi-asserted-by":"publisher","first-page":"100780","DOI":"10.1016\/j.modpat.2025.100780","volume":"38","author":"I Abukhiran","year":"2025","unstructured":"Abukhiran I, Neyaz A, Kop M, et al. Optimal approaches to grading enteropancreatic neuroendocrine tumors using Ki-67 proliferation index: hotspot and whole-slide digital quantitative analysis. Mod Pathol. 2025;38:100780. https:\/\/doi.org\/10.1016\/j.modpat.2025.100780.","journal-title":"Mod Pathol."},{"key":"18887_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13000","volume":"33","author":"K Kankava","year":"2021","unstructured":"Kankava K, Maisonneuve P, Mangogna A, et al. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: grade, mesenteric tumour deposits, and emerging novelties. J Neuroendocrinol. 2021;33:e13000. https:\/\/doi.org\/10.1111\/jne.13000.","journal-title":"J Neuroendocrinol."},{"key":"18887_CR34","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.3390\/cancers14122911","volume":"14","author":"S Xu","year":"2022","unstructured":"Xu S, Ye C, Chen R, Li Q, Ruan J. The landscape and clinical application of the tumor microenvironment in gastroenteropancreatic neuroendocrine neoplasms. Cancers. 2022;14:2911. https:\/\/doi.org\/10.3390\/cancers14122911.","journal-title":"Cancers."},{"key":"18887_CR35","doi-asserted-by":"publisher","first-page":"909180","DOI":"10.3389\/fendo.2022.909180","volume":"13","author":"EJ Doornebal","year":"2022","unstructured":"Doornebal EJ, Harris N, Riva A, et al. Human immunocompetent model of neuroendocrine liver metastases recapitulates patient-specific tumour microenvironment. Front Endocrinol. 2022;13:909180. https:\/\/doi.org\/10.3389\/fendo.2022.909180.","journal-title":"Front Endocrinol."},{"key":"18887_CR36","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1078-0432.CCR-16-1147","volume":"23","author":"JY Kim","year":"2017","unstructured":"Kim JY, Brosnan-Cashman JA, An S, et al. Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clin Cancer Res. 2017;23:1598\u2013606. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1147.","journal-title":"Clin Cancer Res."},{"key":"18887_CR37","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0305","volume":"32","author":"AVD Verschuur","year":"2025","unstructured":"Verschuur AVD, Chen L, Van Dijkum EJ, et al. Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective. Endocr Relat Cancer. 2025;32:e240305. https:\/\/doi.org\/10.1530\/ERC-24-0305.","journal-title":"Endocr Relat Cancer."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18887-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18887-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18887-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:48:35Z","timestamp":1773330515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18887-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["18887"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18887-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thorvardur R. Halfdanarson served on the consulting\/advisory board for Ipsen, TerSera, ScioScientifc, Curium, Advanced Accelerator Applications (a Novartis company), Terumo, ITM Isotopen Technologien Muenchen, Exelixis, Boehringer-Ingelheim, Biomea Fusion, Sanofi, and Crinetics. Dr. Halfdanarson received research support from Thermo Fisher Scientific, Advanced Accelerator Applications (a Novartis company), Camurus, Crinetics, ITM Isotopen Technologien Muenchen, Rezolute, and Perspective Therapeutics. Cornelius Thiels: serves on the consulting\/advisory board for Boston Scientific and consults for apoQlar medical. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}